The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies...
Read moreCIBBIM Nanomedicine awarded at the National Congress of Paediatric Nephrology
Pre-doctoral researcher Mónica Vall, from the research group in Renal Physiopathology – CIBBIM Nanomedicine led by Dr. Anna Meseguer, won the prize for the best poster – short communication from the XLIII National Congress of...
Read moreDr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society
Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will...
Read moreA new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the highest number of active research projects in Nanomedicine of Europe
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group...
Read moreThe EVO-NANO project will allow testing the behavior of nanoparticles within a tumor
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project...
Read moreApril, Fabry disease awareness month
The Fabry International Network (FIN) association has established the month of April as the «month of Fabry» to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry disease is a...
Read moreDr. Simó Schwartz Jr, appointed editorial Board member of the Precision Nanomedicine journal
In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the...
Read moreThe team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz...
Read moreThe Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or...
Read moreAsdent donates more than 114,000 euros for the investigation of Dent’s disease in Vall d’Hebron
Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and...
Read moreProven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer
The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and...
Read moreProven that a protein produced by the kidney could become a therapeutic target for the metabolic syndrome
A study led by Dr. Anna Meseguer, chief of the group of research CIBBIM-Nanomedicine Renal Pathophysiology of the Vall d’Hebron Research Institute (VHIR), has showed the role of the KAP protein in the control of the development of the metabolic...
Read more